Annals of Indian Academy of Neurology
  Users Online: 965 Home | About the Journal | InstructionsCurrent Issue | Back IssuesLogin      Print this page Email this page  Small font size Default font size Increase font size
Year : 2015  |  Volume : 18  |  Issue : 5  |  Page : 30-34

Newer therapies for multiple sclerosis

Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom

Correspondence Address:
Alasdair Coles
Department of Clinical Neurosciences, Clifford Albutt Building, Level 4, Cambridge Biomedical Campus, CB2 0AH, Cambridge
United Kingdom
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0972-2327.164824

Rights and Permissions

The newer immunotherapies for multiple sclerosis (fingolimod, natalizumab, dimethyl fumarate, teriflunomide, alemtuzumab) offer advantages of efficacy or tolerability over the injectable therapies of the 1990s. But they also have greater risks. As further treatments emerge (daclizumab and ocrelizumab are likely to be licensed in the next two years), the physician needs to be able to place them within a complex landscape of drugs and a specific treatment strategy, which may be an "escalation" or "induction" approach. Whilst on treatment, neurologist and patient need to be vigilant to signs of disease breakthrough or adverse effects.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded240    
    Comments [Add]    
    Cited by others 1    

Recommend this journal